IN8bio, Inc. (NASDAQ:INAB) Short Interest Update

IN8bio, Inc. (NASDAQ:INAB) saw a large decline in short interest in the month of January. As of January 31st, there was short interest totalling 433,200 shares, a decline of 51.9% from the January 15th total of 899,800 shares. Based on an average daily trading volume, of 4,110,000 shares, the short-interest ratio is currently 0.1 days. Currently, 0.8% of the company’s shares are sold short.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and issued a $8.00 price objective on shares of IN8bio in a research report on Wednesday.

IN8bio Price Performance

IN8bio stock opened at $0.29 on Friday. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.84 and a quick ratio of 1.84. IN8bio has a 1 year low of $0.22 and a 1 year high of $1.74. The firm has a 50-day moving average of $0.28 and a two-hundred day moving average of $0.36.

IN8bio (NASDAQ:INAB) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.01). Equities analysts anticipate that IN8bio will post -0.56 EPS for the current fiscal year.

Institutional Investors Weigh In On IN8bio

Several large investors have recently modified their holdings of the business. BIOS Capital Management LP bought a new stake in shares of IN8bio in the 4th quarter valued at about $2,212,000. AIGH Capital Management LLC raised its holdings in shares of IN8bio by 269.7% in the 4th quarter. AIGH Capital Management LLC now owns 6,191,865 shares of the company’s stock valued at $1,593,000 after purchasing an additional 4,517,227 shares in the last quarter. Franklin Resources Inc. bought a new stake in shares of IN8bio in the 4th quarter valued at about $1,465,000. Sigma Planning Corp raised its holdings in shares of IN8bio by 22.3% in the 4th quarter. Sigma Planning Corp now owns 1,041,380 shares of the company’s stock valued at $268,000 after purchasing an additional 190,100 shares in the last quarter. Finally, Geode Capital Management LLC raised its holdings in shares of IN8bio by 56.5% in the 4th quarter. Geode Capital Management LLC now owns 515,193 shares of the company’s stock valued at $133,000 after purchasing an additional 185,919 shares in the last quarter. Institutional investors own 92.05% of the company’s stock.

About IN8bio

IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.